Dabigatran versus vitamin K antagonists in patients with atrial fibrillation and valvular heart disease

31 August 2019 (00:00 - 00:00)

Organised by:

Sign in to view the resources

Sign in for access options

About the speaker

Doctor Jarl Emanuel Strange

Herlev and Gentofte Hospital, Copenhagen (Denmark)

9 More presentations in this session

Presentation thumbnail

Performance of the HAS-BLED, ATRIA, and PRECISE-DAPT Bleeding Risk Scores in Atrial Fibrillation Patients Using Antiplatelet Agents or Oral Anticoagulants

Mr J. Choi (Busan, KR)

Abstract Slides

Presentation thumbnail

Comparing the effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in the elderly asian patients with atrial fibrillation

Doctor T. Chao (Taipei, TW)

Presentation thumbnail

Comparative effectiveness and safety of non-VKA oral anticoagulants versus warfarin in non-valvular atrial fibrillation patients with differential treatment duration: an ARISTOPHANES study analysis

Ms A. Kang (Princeton, US)

Abstract Slides

Presentation thumbnail

Comparative safety of factor-xa inhibitors vs phenprocoumon in patients with non-valvular atrial fibrillation and renal disease - insights from the RELOADED study

Professor H. Bonnemeier (Luebeck, DE)

Abstract Slides

Presentation thumbnail

Risk prediction of atrial fibrillation in the community combining biomarkers and genetics

Doctor C. Boerschel (Hamburg, DE)

Access the full session

Session thumbnail

Poster Session 5 - Atrial fibrillation and oral anticoagulation 6

The Event

ESC Congress 2019

31 August - 4 September 2019

You may be interested in

Congress Presentation

State-of-the-art lecture on stroke prevention in atrial fibrillation

Congress Presentation

Treatment strategies for atrial fibrillation in heart failure - discussion

Congress Presentation

Interactive discussion and Q&A

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources